- Home
- DARE vs VRCA Comparison
DARE vs VRCA Comparison
Compare DARE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- VRCA
- Stock Information
- Founded
- DARE 2015
- VRCA 2013
- Country
- DARE United States
- VRCA United States
- Employees
- DARE N/A
- VRCA N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- DARE Health Care
- VRCA Health Care
- Exchange
- DARE Nasdaq
- VRCA Nasdaq
- Market Cap
- DARE 28.6M
- VRCA 32.7M
- IPO Year
- DARE N/A
- VRCA 2018
- Fundamental
- Price
- DARE $1.91
- VRCA $3.77
- Analyst Decision
- DARE Strong Buy
- VRCA Hold
- Analyst Count
- DARE 2
- VRCA 2
- Target Price
- DARE $10.00
- VRCA N/A
- AVG Volume (30 Days)
- DARE 173.3K
- VRCA 247.5K
- Earning Date
- DARE 11-13-2025
- VRCA 11-06-2025
- Dividend Yield
- DARE N/A
- VRCA N/A
- EPS Growth
- DARE N/A
- VRCA N/A
- EPS
- DARE N/A
- VRCA N/A
- Revenue
- DARE N/A
- VRCA $14,704,000.00
- Revenue This Year
- DARE $5,401.89
- VRCA $332.45
- Revenue Next Year
- DARE $6,257.18
- VRCA $12.85
- P/E Ratio
- DARE N/A
- VRCA N/A
- Revenue Growth
- DARE N/A
- VRCA 5.72
- 52 Week Low
- DARE $1.76
- VRCA $3.28
- 52 Week High
- DARE $9.19
- VRCA $13.60
- Technical
- Relative Strength Index (RSI)
- DARE 43.71
- VRCA 44.18
- Support Level
- DARE $1.76
- VRCA $3.37
- Resistance Level
- DARE $1.99
- VRCA $3.99
- Average True Range (ATR)
- DARE 0.10
- VRCA 0.25
- MACD
- DARE -0.01
- VRCA 0.03
- Stochastic Oscillator
- DARE 41.44
- VRCA 45.12
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.